|
12 Companies |
|
20 Products |
|
20 Products |
|
29 Mechanisms of Action |
|
0 Trials |
|
89 News |
|
| 12» |
- || Avastin (bevacizumab) / Roche
Trial completion, Combination therapy: SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors (clinicaltrials.gov) - Mar 6, 2019
P2, N=25, Completed, Sponsor: Sarcoma Alliance for Research through Collaboration
Active, not recruiting --> Completed
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment change, Metastases: Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors (clinicaltrials.gov) - Sep 18, 2018
P2, N=48, Completed, Sponsor: Sarcoma Alliance for Research through Collaboration
Active, not recruiting --> Completed N=74 --> 48
- | emvododstat (PTC299) / PTC Therap
Enrollment change, Trial termination: PTC299 for Treatment of Neurofibromatosis Type 2 (clinicaltrials.gov) - Aug 28, 2018
P2, N=11, Terminated, Sponsor: PTC Therapeutics
N=74 --> 48 N=25 --> 11 | Suspended --> Terminated
- Trial completion: Cochlear Implantation After Labyrinthectomy or a Translabyrinthine Surgical Approach (clinicaltrials.gov) - Jan 9, 2018
P=N/A, N=10, Completed, Sponsor: University of North Carolina, Chapel Hill
N=25 --> 11 | Suspended --> Terminated Active, not recruiting --> Completed
- | alisertib (MLN8237) / Puma
Trial completion, Trial primary completion date, Metastases: Alisertib in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Dec 19, 2017
P2, N=72, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Suspended --> Completed | Trial primary completion date: Feb 2016 --> Aug 2015
- Enrollment closed: Cochlear Implantation After Labyrinthectomy or a Translabyrinthine Surgical Approach (clinicaltrials.gov) - Jun 8, 2017
P=N/A, N=10, Active, not recruiting, Sponsor: University of North Carolina, Chapel Hill
Suspended --> Completed | Trial primary completion date: Feb 2016 --> Aug 2015 Recruiting --> Active, not recruiting
- | everolimus / Generic mfg.
Trial completion, Monotherapy: AFINF2: Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients (clinicaltrials.gov) - May 23, 2017
P2, N=10, Completed, Sponsor: Assistance Publique - H
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Enrollment change, Trial withdrawal, Trial primary completion date: Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors (clinicaltrials.gov) - Apr 28, 2017
P=N/A, N=0, Withdrawn, Sponsor: Sue O'Dorisio
Active, not recruiting --> Completed N=30 --> 0 | Suspended --> Withdrawn | Trial primary completion date: Dec 2018 --> Mar 2017
- || dasatinib / Generic mfg.
Trial primary completion date, Metastases: Trial of Dasatinib in Advanced Sarcomas (clinicaltrials.gov) - Oct 13, 2016
P2, N=386, Active, not recruiting, Sponsor: Sarcoma Alliance for Research through Collaboration
N=30 --> 0 | Suspended --> Withdrawn | Trial primary completion date: Dec 2018 --> Mar 2017 Trial primary completion date: Jun 2015 --> Dec 2016
- Avastin (bevacizumab) / Roche
Trial primary completion date, Combination therapy: SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors (clinicaltrials.gov) - Oct 13, 2016
P2, N=25, Active, not recruiting, Sponsor: Sarcoma Alliance for Research through Collaboration
Trial primary completion date: Jun 2015 --> Dec 2016 Trial primary completion date: Sep 2016 --> Jun 2017
- Trial primary completion date: Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors (clinicaltrials.gov) - Sep 8, 2016
P=N/A, N=30, Suspended, Sponsor: O'Dorisio, M S
Trial primary completion date: Sep 2016 --> Jun 2017 Trial primary completion date: Jul 2016 --> Dec 2018
- Trial completion, Enrollment change: Hippocampal Radiation Exposure and Memory (clinicaltrials.gov) - Jun 23, 2016
P=N/A, N=1, Completed, Sponsor: University Health Network, Toronto
Trial primary completion date: Jul 2016 --> Dec 2018 Recruiting --> Completed | N=30 --> 1
- Trial primary completion date: Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors (clinicaltrials.gov) - Jun 21, 2016
P=N/A, N=30, Suspended, Sponsor: O'Dorisio, M S
Recruiting --> Completed | N=30 --> 1 Trial primary completion date: Jul 2015 --> Jul 2016
- cixutumumab (IMC A12) / Eli Lilly
Trial completion, Metastases: Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - May 19, 2016
P1, N=30, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jul 2015 --> Jul 2016 Active, not recruiting --> Completed
- | Endostar (recombinant human endostatin) / Simcere
Trial completion: Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors (clinicaltrials.gov) - Apr 15, 2016
P2, N=20, Completed, Sponsor: Beijing Tiantan Hospital
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Tasigna (nilotinib) / Novartis, Inhibikase
Enrollment change, Trial termination: A Study of Nilotinib in Growing Vestibular Schwannomas (clinicaltrials.gov) - Mar 14, 2016
P2, N=2, Terminated, Sponsor: University Health Network, Toronto
Active, not recruiting --> Completed N=90 --> 2 | Recruiting --> Terminated; Study PI passed away We had trouble recruiting for the drug arm
- Avastin (bevacizumab) / Roche
Trial primary completion date, Combination therapy: SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors (clinicaltrials.gov) - Mar 7, 2016
P2, N=25, Active, not recruiting, Sponsor: Sarcoma Alliance for Research through Collaboration
N=90 --> 2 | Recruiting --> Terminated; Study PI passed away We had trouble recruiting for the drug arm Trial primary completion date: Feb 2016 --> Sep 2016
- alisertib (MLN8237) / Puma
Enrollment change, Metastases: Alisertib in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Feb 3, 2016
P2, N=72, Suspended, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Feb 2016 --> Sep 2016 N=135 --> 72
- Endostar (recombinant human endostatin) / Simcere
Trial primary completion date: Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors (clinicaltrials.gov) - Jan 17, 2016
P2, N=20, Active, not recruiting, Sponsor: Beijing Tiantan Hospital
N=135 --> 72 Trial primary completion date: Dec 2015 --> Mar 2016
- Enrollment change: Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype (clinicaltrials.gov) - Nov 14, 2015
P=N/A, N=65, Completed, Sponsor: Massachusetts General Hospital
Trial primary completion date: Dec 2015 --> Mar 2016 N=100 --> 65
- Votrient (pazopanib) / Novartis, BeiGene
Trial primary completion date, Combination therapy: Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) (clinicaltrials.gov) - Nov 9, 2015
P1/2, N=5, Terminated, Sponsor: Memorial Sloan Kettering Cancer Center
N=100 --> 65 Trial primary completion date: Nov 2014 --> Nov 2015
- alisertib (MLN8237) / Puma
Enrollment change, Trial primary completion date, Metastases: Alisertib in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Oct 7, 2015
P2, N=135, Suspended, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Nov 2014 --> Nov 2015 N=59 --> 135 | Trial primary completion date: Aug 2015 --> Feb 2016
- RG4733 / Roche
Trial completion, Enrollment change, Trial primary completion date: RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma (clinicaltrials.gov) - Sep 29, 2015
P1, N=22, Completed, Sponsor: National Cancer Institute (NCI)
N=59 --> 135 | Trial primary completion date: Aug 2015 --> Feb 2016 Active, not recruiting --> Completed | N=34 --> 22 | Trial primary completion date: May 2017 --> Jun 2013
- Votrient (pazopanib) / Novartis, BeiGene
Trial primary completion date, Combination therapy: Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) (clinicaltrials.gov) - Sep 24, 2015
P1/2, N=5, Terminated, Sponsor: Memorial Sloan Kettering Cancer Center
Active, not recruiting --> Completed | N=34 --> 22 | Trial primary completion date: May 2017 --> Jun 2013 Trial primary completion date: Aug 2015 --> Nov 2014
- alisertib (MLN8237) / Puma
Enrollment change, Trial primary completion date, Metastases: Alisertib in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Sep 16, 2015
P2, N=59, Suspended, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Aug 2015 --> Nov 2014 N=135 --> 59 | Trial primary completion date: Feb 2016 --> Aug 2015
- Trial completion: Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype (clinicaltrials.gov) - Aug 28, 2015
P=N/A, N=100, Completed, Sponsor: Massachusetts General Hospital
N=135 --> 59 | Trial primary completion date: Feb 2016 --> Aug 2015 Active, not recruiting --> Completed
- alisertib (MLN8237) / Puma
Trial primary completion date, Metastases: Alisertib in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Jul 14, 2015
P2, N=135, Suspended, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Trial primary completion date: Aug 2015 --> Feb 2016
- everolimus / Generic mfg.
Trial completion, Enrollment change: Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2 (clinicaltrials.gov) - Jul 9, 2015
P2, N=11, Completed, Sponsor: New York University School of Medicine
Trial primary completion date: Aug 2015 --> Feb 2016 Active, not recruiting --> Completed | N=25 --> 11
- RG4733 / Roche, Erivedge (vismodegib) / Roche
Trial completion, Enrollment change, Combination therapy, Metastases: Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - May 26, 2015
P1b, N=78, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | N=25 --> 11 Active, not recruiting --> Completed | N=120 --> 78
- cixutumumab (IMC A12) / Eli Lilly
Enrollment change, Metastases: Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - May 7, 2015
P1, N=30, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | N=120 --> 78 N=50 --> 30
- Trial suspension: Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors (clinicaltrials.gov) - Apr 22, 2015
P=N/A, N=30, Suspended, Sponsor: University of Iowa
N=50 --> 30 Recruiting --> Suspended
- Enrollment closed: Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype (clinicaltrials.gov) - Feb 27, 2015
P=N/A, N=100, Active, not recruiting, Sponsor: Massachusetts General Hospital
Recruiting --> Suspended Recruiting --> Active, not recruiting
- alisertib (MLN8237) / Puma
Trial primary completion date, Metastases: Alisertib in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Feb 12, 2015
P2, N=135, Suspended, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Trial primary completion date: Mar 2015 --> Aug 2015
- Votrient (pazopanib) / Novartis, BeiGene
Enrollment change, Trial termination, Combination therapy: Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) (clinicaltrials.gov) - Dec 19, 2014
P1/2, N=5, Terminated, Sponsor: Memorial Sloan-Kettering Cancer Center
Trial primary completion date: Mar 2015 --> Aug 2015 N=61 --> 5 | Active, not recruiting --> Terminated; Lack of accrual
- ||| dasatinib / Generic mfg.
Enrollment change, Trial primary completion date, Metastases: Trial of Dasatinib in Advanced Sarcomas (clinicaltrials.gov) - Dec 19, 2014
P2, N=386, Active, not recruiting, Sponsor: Sarcoma Alliance for Research through Collaboration
N=61 --> 5 | Active, not recruiting --> Terminated; Lack of accrual N=502 --> 386 | Trial primary completion date: Dec 2014 --> Jun 2015
- |||| Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion, Trial primary completion date, Metastases: Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors (clinicaltrials.gov) - Dec 19, 2014
P2, N=74, Completed, Sponsor: Sarcoma Alliance for Research through Collaboration
N=502 --> 386 | Trial primary completion date: Dec 2014 --> Jun 2015 Active, not recruiting --> Completed | Trial primary completion date: Feb 2014 --> Jun 2014
- alisertib (MLN8237) / Puma
Trial primary completion date, Metastases: Alisertib in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Dec 17, 2014
P2, N=135, Suspended, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Trial primary completion date: Feb 2014 --> Jun 2014 Trial primary completion date: Aug 2014 --> Mar 2015
- Clinical: Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype (clinicaltrials.gov) - Nov 23, 2014
P=N/A, N=100, Recruiting, Sponsor: Massachusetts General Hospital
- RG4733 / Roche, Erivedge (vismodegib) / Roche
Trial primary completion date, Combination therapy, Metastases: Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Nov 7, 2014
P1b, N=120, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Aug 2014 --> Mar 2015 Trial primary completion date: Nov 2014 --> Apr 2015
- ||| Votrient (pazopanib) / Novartis, BeiGene
Enrollment closed, Combination therapy: Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) (clinicaltrials.gov) - Nov 6, 2014
P1/2, N=61, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Trial primary completion date: Nov 2014 --> Apr 2015 Recruiting --> Active, not recruiting
- Trial primary completion date: Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors (clinicaltrials.gov) - Oct 15, 2014
P=N/A, N=30, Recruiting, Sponsor: University of Iowa
Recruiting --> Active, not recruiting Trial primary completion date: Jul 2014 --> Jul 2015
- RG4733 / Roche, Erivedge (vismodegib) / Roche
Enrollment closed, Combination therapy, Metastases: Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Oct 10, 2014
P1b, N=120, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jul 2014 --> Jul 2015 Recruiting --> Active, not recruiting
- | Avastin (bevacizumab) / Roche
Enrollment open, Combination therapy: SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors (clinicaltrials.gov) - Sep 30, 2014
P2, N=25, Recruiting, Sponsor: Sarcoma Alliance for Research through Collaboration
Recruiting --> Active, not recruiting Active, not recruiting --> Recruiting
- Votrient (pazopanib) / Novartis, BeiGene
Trial primary completion date, Combination therapy: Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) (clinicaltrials.gov) - Aug 7, 2014
P1/2, N=61, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Recruiting Trial primary completion date: Aug 2014 --> Aug 2015
- alisertib (MLN8237) / Puma
Trial suspension, Metastases: Alisertib in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Aug 1, 2014
P2, N=135, Suspended, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Aug 2014 --> Aug 2015 Recruiting --> Suspended
- RG4733 / Roche
Trial primary completion date: RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma (clinicaltrials.gov) - Jul 30, 2014
P1, N=34, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Suspended Trial primary completion date: Jul 2014 --> May 2017
- RG4733 / Roche, Erivedge (vismodegib) / Roche
Trial primary completion date, Combination therapy, Metastases: Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Jul 21, 2014
P1b, N=120, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jul 2014 --> May 2017 Trial primary completion date: Aug 2014 --> Nov 2014
- Enrollment change: Recovery of Visual Acuity in People With Vestibular Deficits (clinicaltrials.gov) - Jul 21, 2014
P=N/A, N=23, Completed, Sponsor: Emory University
Trial primary completion date: Aug 2014 --> Nov 2014 N=98 --> 23
- Clinical: Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors (clinicaltrials.gov) - Jul 18, 2014
P=N/A, N=30, Recruiting, Sponsor: University of Iowa
- | Endostar (recombinant human endostatin) / Simcere
Enrollment closed: Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors (clinicaltrials.gov) - Jul 15, 2014
P2, N=20, Active, not recruiting, Sponsor: Beijing Tiantan Hospital
N=98 --> 23 Recruiting --> Active, not recruiting